Evommune (EVMN) Other Non-Current Liabilities (2024 - 2025)
Evommune (EVMN) reported Other Non-Current Liabilities of $261000.0 for Q3 2025, down 51.21% on a QoQ basis from $535000.0 in Q4 2024.
Evommune (EVMN) has 2 years of Other Non-Current Liabilities data on file, last reported at $261000.0 in Q3 2025.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $261000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $261000.0 (changed N/A YoY) and the FY2024 annual result came in at $535000.0, changed N/A from the prior year.
- Other Non-Current Liabilities slipped to $261000.0 in Q3 2025 per EVMN's latest filing, from $535000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $535000.0 in Q4 2024 and bottomed at $261000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Evommune | 744.11 Mn | 532.65 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 261,000.00 |
| Dec 31, 2024 | 535,000.00 |